| 标题 |
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Ralf Gutzmer; Daniil Stroyakovskiy; Helen Gogas; Caroline Robert; Karl D. Lewis; et al 出版日期:2020-06-01 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)